多发性骨髓瘤对Venetoclax敏感性关联B细胞基因表达
该研究探讨多发性骨髓瘤对Venetoclax敏感性的生物学基础。通过敲低cyclin D1、分析31株细胞系和25例患者样本,发现BIM与BCL2结合及B细胞基因表达与敏感性相关,细胞表面标志物可预测反应且独立于t(11;14)。
要点
- 敲低cyclin D1不诱导Venetoclax耐药,不支持其直接作用。
- BIM与BCL2结合及BIM敲除影响Venetoclax敏感性。
- B细胞基因表达和表观程序与Venetoclax敏感相关,细胞表面标志物可作独立于t(11;14)的生物标志物。
核心结论
- B细胞生物学残余与BCL2依赖性相关,提示独立于t(11;14)的Venetoclax敏感性生物标志物。
研究设计与样本
- 研究31株骨髓瘤细胞系和25例患者样本的Venetoclax敏感性。
- 进行cyclin D1敲低、BIM敲除、RNA测序和ATAC测序分析。
主要发现
- 敲低cyclin D1不诱导Venetoclax耐药。
- BIM与BCL2结合与Venetoclax反应相关,BIM敲除降低敏感性。
- Venetoclax敏感骨髓瘤中B细胞基因表达富集,但无单一基因一致区分敏感与耐药。
- 一组细胞表面标志物在21例患者样本中与离体预测反应良好相关。
- ATAC测序显示敏感细胞表观程序更类似B细胞,富集BATF等碱性亮氨酸拉链结构域结合基序。
临床怎么用
- 细胞表面标志物面板可能作为独立于t(11;14)的生物标志物预测Venetoclax反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax is a highly potent, selective BCL2 inhibitor capable of inducing apoptosis in cells dependent on BCL2 for survival. Most myeloma is MCL1-dependent; however, a subset of myeloma enriched for translocation t(11;14) is codependent on BCL2 and thus sensitive to venetoclax. The biology underlying this heterogeneity remains poorly understood. We show that knockdown of cyclin D1 does not induce resistance to venetoclax, arguing against a direct role for cyclin D1 in venetoclax sensitivity. To identify other factors contributing to venetoclax response, we studied a panel of 31 myeloma cell lines and 25 patient samples tested for venetoclax sensitivity. In cell lines, we corroborated our previous observation that BIM binding to BCL2 correlates with venetoclax response and further showed that knockout of BIM results in decreased venetoclax sensitivity. RNA-sequencing analysis identified expression of B-cell genes as enriched in venetoclax-sensitive myeloma, although no single gene consistently delineated sensitive and resistant cells. However, a panel of cell surface makers correlated well with ex vivo prediction of venetoclax response in 21 patient samples and may serve as a biomarker independent of t(11;14). Assay for transposase-accessible chromatin sequencing of myeloma cell lines also identified an epigenetic program in venetoclax-sensitive cells that was more similar to B cells than that of venetoclax-resistant cells, as well as enrichment for basic leucine zipper domain-binding motifs such as BATF. Together, these data indicate that remnants of B-cell biology are associated with BCL2 dependency and point to novel biomarkers of venetoclax-sensitive myeloma independent of t(11;14).
引用
- Gupta VA, Barwick BG, Matulis SM, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021. PMID: 33649772. doi:10.1182/blood.2020007899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。